<?xml version='1.0' encoding='utf-8'?>
<document id="30049303"><sentence text="Effect of coadministration of metformin with mirogabalin: Results from a phase 1, randomized, open-label, drug-drug interaction study ."><entity charOffset="30-39" id="DDI-PubMed.30049303.s1.e0" text="metformin" /><entity charOffset="45-56" id="DDI-PubMed.30049303.s1.e1" text="mirogabalin" /><pair ddi="false" e1="DDI-PubMed.30049303.s1.e0" e2="DDI-PubMed.30049303.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30049303.s1.e0" e2="DDI-PubMed.30049303.s1.e1" /></sentence><sentence text="Mirogabalin, a selective voltage-dependent calcium channel α2δ ligand under development for treatment of neuropathic pain, may be coadministered with metformin in patients with type 2 diabetes mellitus who have diabetic peripheral neuropathic pain"><entity charOffset="0-11" id="DDI-PubMed.30049303.s2.e0" text="Mirogabalin" /><entity charOffset="43-50" id="DDI-PubMed.30049303.s2.e1" text="calcium" /><entity charOffset="150-159" id="DDI-PubMed.30049303.s2.e2" text="metformin" /><pair ddi="false" e1="DDI-PubMed.30049303.s2.e0" e2="DDI-PubMed.30049303.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30049303.s2.e0" e2="DDI-PubMed.30049303.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30049303.s2.e0" e2="DDI-PubMed.30049303.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30049303.s2.e1" e2="DDI-PubMed.30049303.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30049303.s2.e1" e2="DDI-PubMed.30049303.s2.e2" /></sentence><sentence text=" A randomized, open-label, single-dose, 3-treatment, 3-period crossover study evaluated the pharmacokinetics (PK) and safety of mirogabalin and metformin upon coadministration"><entity charOffset="128-139" id="DDI-PubMed.30049303.s3.e0" text="mirogabalin" /><entity charOffset="144-153" id="DDI-PubMed.30049303.s3.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.30049303.s3.e0" e2="DDI-PubMed.30049303.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30049303.s3.e0" e2="DDI-PubMed.30049303.s3.e1" /></sentence><sentence text=" Eligible subjects received 3 treatments separated by a 7-day washout period: 1 oral dose of mirogabalin 15 mg; 1 oral dose of metformin 850 mg; and coadministration of mirogabalin 15 mg with metformin 850 mg"><entity charOffset="93-104" id="DDI-PubMed.30049303.s4.e0" text="mirogabalin" /><entity charOffset="127-136" id="DDI-PubMed.30049303.s4.e1" text="metformin" /><entity charOffset="169-180" id="DDI-PubMed.30049303.s4.e2" text="mirogabalin" /><entity charOffset="192-201" id="DDI-PubMed.30049303.s4.e3" text="metformin" /><pair ddi="false" e1="DDI-PubMed.30049303.s4.e0" e2="DDI-PubMed.30049303.s4.e0" /><pair ddi="false" e1="DDI-PubMed.30049303.s4.e0" e2="DDI-PubMed.30049303.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30049303.s4.e0" e2="DDI-PubMed.30049303.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30049303.s4.e0" e2="DDI-PubMed.30049303.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30049303.s4.e1" e2="DDI-PubMed.30049303.s4.e1" /><pair ddi="false" e1="DDI-PubMed.30049303.s4.e1" e2="DDI-PubMed.30049303.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30049303.s4.e1" e2="DDI-PubMed.30049303.s4.e3" /><pair ddi="false" e1="DDI-PubMed.30049303.s4.e2" e2="DDI-PubMed.30049303.s4.e2" /><pair ddi="false" e1="DDI-PubMed.30049303.s4.e2" e2="DDI-PubMed.30049303.s4.e3" /></sentence><sentence text=" PK assessments included maximum observed plasma concentration (Cmax); time of maximum plasma concentration; area under the concentration-time curve from time 0 to the last quantifiable concentration, and from 0 to infinity (AUClast and AUC0-inf, respectively)" /><sentence text=" Safety assessments included adverse event (AE) monitoring and physical and clinical laboratory evaluations" /><sentence text=" 21 healthy men with a mean age of 30" /><sentence text="4 years were enrolled and completed the study" /><sentence text=" Geometric least square means ratios (coadministration vs" /><sentence text=" alone; 90% confidence interval) for metformin Cmax, AUClast, and AUC0-inf were 1"><entity charOffset="37-46" id="DDI-PubMed.30049303.s10.e0" text="metformin" /></sentence><sentence text="00 (0" /><sentence text="95 - 1" /><sentence text="05), 1" /><sentence text="04 (1" /><sentence text="00 - 1" /><sentence text="07), and 1" /><sentence text="03 (1" /><sentence text="00 - 1" /><sentence text="07), respectively; ratios for mirogabalin were 0"><entity charOffset="30-41" id="DDI-PubMed.30049303.s19.e0" text="mirogabalin" /></sentence><sentence text="94 (0" /><sentence text="87 - 1" /><sentence text="02), 0" /><sentence text="99 (0" /><sentence text="95 - 1" /><sentence text="04), and 1" /><sentence text="00 (0" /><sentence text="96 - 1" /><sentence text="04), respectively" /><sentence text=" Three subjects reported treatment-emergent AEs: dyspepsia, headache, and increased hepatic enzymes (resolved upon follow-up without sequelae)" /><sentence text=" There were no deaths, serious AEs, or discontinuations due to AEs" /><sentence text=" Coadministration of mirogabalin and metformin is well tolerated in healthy subjects with no evidence of a drug-drug interaction"><entity charOffset="21-32" id="DDI-PubMed.30049303.s31.e0" text="mirogabalin" /><entity charOffset="37-46" id="DDI-PubMed.30049303.s31.e1" text="metformin" /><pair ddi="false" e1="DDI-PubMed.30049303.s31.e0" e2="DDI-PubMed.30049303.s31.e0" /><pair ddi="false" e1="DDI-PubMed.30049303.s31.e0" e2="DDI-PubMed.30049303.s31.e1" /></sentence><sentence text=" " /><sentence text="" /></document>